Manitoba Health

Information for Health Professionals

• Pharmacy Claims Submission Procedures and Audit
• Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary
• Submitting New or Updated Pharmacy Information
• Current Topics & Client Resources
• Additional Client-Related Resources
• Provincial Acts and Regulations
• Contact Information

---

Pharmacy Claims Submission Procedures and Audit

Manitoba Health's current claim submission procedures and audit processes for community pharmacies are available below. (For all documents related to Claim Submission Procedures, the word “Manitoba” refers to “Manitoba Health.")

Notices

• Notice – COVID-19
• Expression of Interest for COVID-19 Oral Antiviral Drug Provision (UPDATED May 3, 2022)
• COVID-19 Oral Antiviral Drug Provision Expression of Interest Form
• Drug Shortage Quantity Restrictions List – Effective May 11, 2020 (UPDATED June 27, 2022)
• Supply Restriction Update
• Prescribing and Dispensing of Drugs to Treat COVID-19
• Drug Shortage – FOREIGN LABELLED DEPO-PROVERA NOTICE
• Drug Shortage – FOREIGN LABELLED SALBUTAMOL NOTICE
• EDS Extension (UPDATED April 2021)
• 30 – Day Supply
• Notice – Pharmacy Software Vendor Price file
  • PSV file July 21, 2022 CHANGES ONLY – FINAL
  • Excel file July 21, 2022 CHANGES ONLY – FINAL
  • PSV file July 21, 2022 COMPLETE DIN LIST INCLUDING CHANGES – FINAL
  • Excel file July 21, 2022 COMPLETE DIN LIST INCLUDING CHANGES – FINAL
• Notice – Tiered Biologics Reimbursement Policy
  • Tiered Biologics Flowsheet (UPDATED June 2022)
  • Tiered Biologics Overview (UPDATED June 2022)
  • Tiered Biologics by Specialty (UPDATED June 2022)
• Notice – Approved Compounds for Pain Management – January 19, 2018

Pharmacy Submission Procedure Manual (DPIN Pharmacy Manual)
The DPIN Pharmacy Manual may be updated from time to time, as communicated directly to pharmacies. The current version includes all Claims Submission Procedures and associated lists/forms provided below.

• Claims Submission Procedure – COVID-19 Oral Antiviral Drug Provision (EFFECTIVE May 20, 2022)
• COVID-19 Oral Antiviral Drug Claim Form – Client Without a Manitoba Health PHIN (EFFECTIVE May 20, 2022)
• Paxlovid Order Form
• Claims Submission Procedure – Uncomplicated Cystitis Assessment (EFFECTIVE March 7, 2022)
• Claims Submission Procedure – Manitoba HIV Medication Program – Anti-Retroviral Therapies (EFFECTIVE July 12, 2021)
• Claims Submission Procedure – Manitoba HIV Medication Program – Post-Exposure Prophylaxis (EFFECTIVE July 26, 2021)
• Manitoba HIV Medication Program Drug List (UPDATED February 24, 2022)
• Claims Submission Procedure – BGTS – Effective March 1, 2021 (UPDATED June 2021)
• Claims Submission Procedure – Levetiracetam 100mg/mL
• Claims Submission Procedure – Premarin Vaginal Cream 0.625mg/g – 30g (Effective August 13, 2021)
• Claims Submission Procedure – Timolol Maleate Eye Drops 0.5% – Effective June 8, 2020
• Claims Submission Procedure – Professional Fee Cap
• Claims Submission Procedure – Oral Oncology Drugs Dispensed at CancerCare Manitoba
  • List of Oral Oncology Drugs Dispensed at CancerCare Manitoba (UPDATED June 2022)
• Claims Submission Procedure – Extemporaneous Products (Compounding)
  • Monitored Drugs Compound List (UPDATED March 31, 2022)
  • PIN Flowsheet
• Claims Submission Procedure – Outsourced Extemporaneous Products
• Claims Submission Procedure – Special Authority Compounding
  • Form – Special Authority Compound Worksheet
• Claims Submission Procedure – Manitoba Designated Drug Shortages
  • Drug Shortage PIN List to June 27, 2022
  • Drug Shortage – Cortef (Foreign Label)
  • Drug Shortage – Depo-Medrol
  • Drug Shortage – NARDIL (Foreign Label)
  • Drug Shortage – TRIFLUOPERAZINE
  • Drug Shortage Compound – COTRIMOXAZOLE 40mg – 8mg per ml Oral Suspension
  • Drug Shortage Compound – DALACIN T 1 Topical Solution
  • Drug Shortage – PROPYLTHIOURACIL (FOREIGN LABEL)
• Claims Submission Procedure – Dispensing Frequency
  • Frequency of Dispensing List (UPDATED May 2019)
  • Form – Frequent Dispensing Authorization
• Claims Submission Procedure – Claims with Cost Exceeding $9999.99
• Claims Submission Procedure – Methadone (UPDATED August 2021)
  • FAQ – Methadone (UPDATED August 2021)
• Claims Submission Procedure – Pharmaceutical Distribution Rate Changes (UPDATED May 2019)
• Claims Submission Procedure – Mifegymiso
• List of Designated High-Cost Drugs for Reduced Pharmaceutical Distribution (UPDATED May 2022)
• FAQ – Pharmacare Audit and Investigations
  • Pharmacy Agreement Schedule “B” – Notice of Professional Fee Change
• Form – Reversal/Adjustment
• Template – Pharmacy Agreement

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs provided here, please contact PDPInfoAudit@gov.mb.ca.

^ top

 

---

Manitoba Drug Benefits Formulary and Manitoba Drug Interchangeability Formulary

About the Manitoba Drug Benefits and Interchangeability Formularies

• Bulletin Archive
  This is the archive of Manitoba Drug Benefits and Interchangeability Formulary Amendments.
• Manitoba Drug Benefits Formulary
  A list of drugs and other items specified as eligible benefits under the Manitoba Pharmacare drug benefit program.
• Manitoba Drug Interchangeability Formulary
  A list of interchangeable drugs, categories and prices specific to drugs listed on the Manitoba Drug Benefits Formulary. Please note that Manitoba Pharmacare will reimburse only up to the lowest price in an interchangeable category for those interchangeable drugs which are Pharmacare benefits.
  Effective date of transition from Regulation to Policy: October 18, 2021.
  
• 2022 Pan-Canadian Price Initiative
• Manitoba Drug Formulary Lookup
  Search the Manitoba Drug Benefits Formulary by brand name, active ingredient, Drug Identification Number (DIN); or more advanced search options such as Therapeutic Classification.
• Manitoba Drug Formulary Glossary of Terms
• EDS
  Certain drugs are approved for coverage under the Exception Drug Status (EDS) Program when the use meets specific criteria as recommended by the Manitoba Drug Standards and Therapeutics Committee (MDSTC).
  Effective October 18, 2021, "Part 3 Exception Drug Status" or "Part 3 benefits" will be referred to as "Exception Drug Status" or "EDS benefits".
  • EDS Application Processing Times
  • Changes to Exception Drug Status (EDS) Approval Process and Expiry Dates
  • Exception Drug Status (EDS) Request Form
  • EDS Request Form: Ajovy
  • EDS Request Form: CGM or FGM (updated Oct. 6, 2021)
  • EDS Request Form: Cholinesterase Inhibitor
  • EDS Request Form: Nucala
  • EDS Request Form: Ofev
  • EDS Request Form: Personal Care Home
  • EDS Indefinite Drug List (updated February 2022)
• pCPA
  The pan-Canadian Pharmaceutical Alliance (pCPA) conducts joint provincial/territorial negotiations for brand name drugs in Canada to achieve greater value for publicly funded drug programs and patients.
• CADTH Common Drug Review (CDR) Reports
  Through the Common Drug Review (CDR) Process, CADTH conducts thorough and objective evaluations of the clinical, economic and patient evidence on drugs, and uses this evaluation to provide reimbursement recommendations and advice to Canada’s federal, provincial and territorial public drug plans.

^ top

 

---

Submitting New or Updated Pharmacy Information

• DPIN Registration Form

^ top

 

---

Current Topics & Client Resources

Pharmacare

• About Pharmacare
  • Applying for Pharmacare
  • Application and Consent Authorization Form
  • General Pharmacare Questions
• Deductible Instalment Payment Program for Pharmacare (DIPPP)
  • DIPPP Guide
  • DIPPP Application, Consent and Authorization Form
• Blood Glucose Test Strip Coverage
• FAQ – New Diabetes Supports – AGM and Insulin Pumps

Naloxone Kits

• Take-Home Naloxone Program

Drug Shortages Canada

• The website for reporting drug shortages and discontinuations in Canada.

^ top

 

---

Provincial Acts and Regulations

Provincial Acts and Regulations are available through the website of the Statutory Publications Office.

• The Prescription Drugs Cost Assistance Act
  • Prescription Drugs Payment of Benefits Regulation
  • Specified Drugs Regulation
    This is the regulation that provides for the benefit lists of specified drugs under The Prescription Drugs Cost Assistance Act. It lists the drugs and criteria for eligibility for the Manitoba Pharmacare program.
    Effective: April 20, 2017
• The Pharmaceutical Act
  • Manitoba Drug Interchangeability Formulary
    This regulation under The Pharmaceutical Act includes a list of interchangeable drugs, categories and prices. Please note that Manitoba Pharmacare will reimburse only up to the lowest price in an interchangeable category for those interchangeable drugs which are Pharmacare benefits.
    Effective: April 20, 2017
• The Personal Health Information Act (PHIA)
  • PHIA - Information for Trustees
  • The Personal Health Information Regulation
    This regulation has no legislative sanction and the original should be consulted for purposes of interpreting and applying the law.

^ top

 

---

Contact Information

Provincial Drug Programs
Manitoba Health
300 Carlton Street
Winnipeg MB R3B 3M9

PDP Information and Audit
PDPInfoAudit@gov.mb.ca
Fax: 204-786-8560

 

 

^ top